Indeterminate Bile Duct Stricture Clinical Trial
Official title:
Optimizing the Role of ERCP in Evaluating Indeterminate Bile Duct Strictures
Differentiating malignant from benign bile duct strictures is a conundrum, since no
diagnostic test is highly sensitive for diagnosing cancer. While ERCP is effective in
palliating obstructive jaundice, standard diagnostic tools in ERCP have a low diagnostic
sensitivity and confirm the stricture's etiology in <50% of cases. During the first ERCP,
standard practice is to obtain routine cytology (RC) using a single brush sample. If this is
not diagnostic, patients often undergo repeat ERCP, endoscopic ultrasound or other,
increasing health care costs. The incremental yield of performing alternate ERCP-based
diagnostic tools during the first ERCP including fluorescence in situ hybridization (FISH),
cholangioscopy w/biopsy and multiple brushes for routine cytology is currently unknown.
There are no studies quantifying the amount of testing utilized to firmly diagnose the
etiology of the stricture, or the most efficient combination of diagnostic tools during the
first ERCP. These are important knowledge deficiencies since a definitive tissue diagnosis
during the first ERCP could reduce the need for downstream tests and expedite treatment,
thereby improving patient-centered and economic outcomes. The added costs of using multiple
tools during the first ERCP may be offset by these benefits.
Among patients with indeterminate bile duct strictures, the investigators hypothesize that a
multimodality approach will be more sensitive without a significant reduction in specificity
compared to multiple brush samples for routine cytology. The investigators will test this
hypothesis using an experimental trial design by randomizing patients during their first
ERCP to multiple brushing samples for cytology vs. a single brush sample for cytology + FISH
+ cholangioscopy w/biopsy. To obtain preliminary data for a definitive multi-center trial,
the investigators propose a pilot and feasibility study to compare the performance
characteristics of each approach by evaluating the prospective clinical course, including
treatment delay, quality of life, and life expectancy for each enrolled patient. If our
hypothesis is validated in a subsequent definitive study, the standard approach to tissue
sampling during the first ERCP may be altered.
| Status | Completed |
| Enrollment | 48 |
| Est. completion date | September 2016 |
| Est. primary completion date | September 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Extrahepatic BDS with no discrete mass on CT/MRI (either or both) - A BDS is defined as a segmental narrowing of the bile duct > 50% of the proximal or distal unaffected duct. - Biochemical evidence of cholestasis (increase in alkaline phosphatase = 2x upper limit of normal ± total bilirubin =2.0mg/dL) Exclusion Criteria: - No clinical suspicion for malignancy - Associated mass seen on CT or MRI - Age =18, pregnancy, incarceration, inability to give informed consent - Inability to undergo standard ERCP (e.g., postsurgical anatomy) - Previous ERCP with sampling of BDS, other than a single brushing specimen sent for routine cytopathology |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic
| Country | Name | City | State |
|---|---|---|---|
| United States | Medical University of South Carolina | Charleston | South Carolina |
| United States | Indiana University Health University Hospital | Indianapolis | Indiana |
| Lead Sponsor | Collaborator |
|---|---|
| Medical University of South Carolina | Boston Scientific Corporation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Performance characteristics | A definite diagnosis of malignancy (i.e., "true positive") will be defined as either 1) a cytological or histological interpretation "positive for malignancy" based on brushing for RC or biopsy; 2) subsequent cytological or histological confirmation of malignancy within one year of the index procedure, via repeat ERCP, surgery, other diagnostic test. If a diagnosis of cancer is not confirmed after one year of follow-up, then the stricture will be classified as non-malignant and the negative cytology, FISH and histology from the index ERCP considered "true negatives." |
12 months | No |
| Secondary | Incremental yield of multiple brushings | The additive role of each additional brushing will be analyzed for 1) adequacy of cellularity for cytological interpretation and 2) assessment of malignancy. The cytopathologist will be asked to interpret each of these outcomes using the first pass only (control group), first two passes only, first three passes only, and so on until all seven brushings are analyzed. The performance characteristics (see primary outcome) will be compared for each incremental brushing, assuming that a single intraductal brushing for RC is the reference standard. | 12 months | No |
| Secondary | Incremental cost effectiveness ratio | Complete data on medical utilization (e.g. hospitalizations, procedures, ambulatory visits) will be collected prospectively using Indiana Network for Patient Care (INPC) health information exchange databases (clinical electronic health record (EHR) and claims). Direct costs associated with the diagnostic evaluation of the indeterminate bile duct stricture (BDS) will be measured in both groups, including those costs associated with the index ERCP and all treatment costs associated with each study arm. | 12 months | No |